摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基-4-氯苯基硼酸频哪醇酯 | 850567-56-5

中文名称
3-氨基-4-氯苯基硼酸频哪醇酯
中文别名
3-氨基-4-氯苯硼酸频那醇酯;3-氨基-4-氯苯硼酸频哪醇酯
英文名称
2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
英文别名
3-amino-4-chlorophenylboronic acid pinacol ester
3-氨基-4-氯苯基硼酸频哪醇酯化学式
CAS
850567-56-5
化学式
C12H17BClNO2
mdl
——
分子量
253.536
InChiKey
KHGJUVPQSMKNFA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    142-144
  • 沸点:
    361.5±32.0 °C(Predicted)
  • 密度:
    1.15±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.22
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    44.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    Xi
  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335

SDS

SDS:8e163cdd468b578115ccc6875f8423ae
查看
Material Safety Data Sheet

Section 1. Identification of the substance
3-Amino-4-chlorophenylboronic acid, pinacol ester
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
3-Amino-4-chlorophenylboronic acid, pinacol ester
Ingredient name:
CAS number: 850567-56-5

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H17B2NO2
Molecular weight: 253.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-bromo-4-(3-chloro-4-fluoroanilino)quinazoline hydrochloride salt3-氨基-4-氯苯基硼酸频哪醇酯potassium carbonate 作用下, 反应 0.3h, 以35%的产率得到6-(3-amino-4-chlorophenyl)-N-(3-chloro-4-fluorophenyl)quinazolin-4-amine
    参考文献:
    名称:
    [EN] COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER
    [FR] COMBINAISON D'INHIBITEURS DE POINTS DE CONTRÔLE POUR LE TRAITEMENT DU CANCER
    摘要:
    一种组合物包括化合物的公式(I)和/或公式(Ia),或其药用可接受的盐,以及至少一种免疫检查点调节剂。预防和治疗癌症的方法包括向需要的受试者施用该组合物的治疗有效量,该组合物包括:化合物的公式(I)和/或公式(Ia),或其药用可接受的盐,以及至少一种免疫检查点调节剂。
    公开号:
    WO2020215037A1
  • 作为产物:
    描述:
    4-氯-3-硝基苯硼酸频哪酯 在 5%-palladium/activated carbon 、 氢气 作用下, 以 甲醇 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 4.0h, 以74%的产率得到3-氨基-4-氯苯基硼酸频哪醇酯
    参考文献:
    名称:
    Sandmeyer型转化合成三甲基锡烷基芳基硼酸酯化合物及其在化学选择性交叉偶联反应中的应用
    摘要:
    描述了一种基于Sandmeyer型反应的合成方法,可从硝基苯胺衍生物中获得锡和硼取代的芳烃。该转化可用于合成一系列官能化的三甲基锡烷基芳基硼酸酯。此外,还探索了Stille和Suzuki-Miyaura交叉偶联反应的化学选择性反应,并通过进行连续的一锅法式Stille和Suzuki-Miyaura交叉偶联反应合成了一系列m-和对-三苯基衍生物。
    DOI:
    10.1021/jo402618r
点击查看最新优质反应信息

文献信息

  • [EN] TLR7/8 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DE TLR7/8 ET LEURS UTILISATIONS
    申请人:MERCK PATENT GMBH
    公开号:WO2018031434A1
    公开(公告)日:2018-02-15
    The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    本发明涉及式I化合物及其药用可接受的组合物,用作TLR7/8拮抗剂。
  • <i>Para</i>-Selective C–H Borylation of Common Arene Building Blocks Enabled by Ion-Pairing with a Bulky Countercation
    作者:Madalina T. Mihai、Benjamin D. Williams、Robert J. Phipps
    DOI:10.1021/jacs.9b07267
    日期:2019.10.2
    The selective functionalization of C–H bonds at the arene para position is highly challenging using transition metal catalysis. Iridium-catalyzed borylation has emerged as a leading technique for arene functionalization, but there are only a handful of strategies for para-selective borylation, which operate on specific substrate classes and use bespoke ligands or catalysts. We describe a remarkably
    使用过渡金属催化对芳烃对位的 C-H 键进行选择性官能化是非常具有挑战性的。铱催化硼化已成为芳烃功能化的领先技术,但对位选择性硼化的策略很少,它们在特定的底物类别上运行并使用定制的配体或催化剂。我们描述了一个非常通用的协议,它导致对一些最常见的芳烃构建块(苯胺、苄胺、苯酚、苄醇)产生对位选择性,并使用标准硼酸化配体。我们的策略取决于将底物轻松转化为硫酸盐或氨基磺酸盐,其中阴离子芳烃组分与四丁基铵阳离子配对。我们假设该阳离子的大部分不利于间位 C-H 硼酸化,
  • [EN] PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS<br/>[FR] DÉRIVÉS PYRROLOPYRIDINEAMINO EN TANT QU'INHIBITEURS DE MPS1
    申请人:CANCER REC TECH LTD
    公开号:WO2012123745A1
    公开(公告)日:2012-09-20
    The present invention relates to the use of certain pyrrolopyridineamino derivatives (hereinafter referred to as "PPA derivatives"), particularly 1H-pyrrolo[3,2-c]pyridine-6- amino derivatives, to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 – also known as TTK) kinases either directly or indirectly via interaction with the Mps kinase itself. In particular, the present invention relates to PPA derivatives for use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of the PPA derivatives, and pharmaceutical compositions comprising them. Formula (I)
    本发明涉及使用特定的吡咯吡啶氨基衍生物(以下简称为“PPA衍生物”),特别是1H-吡咯[3,2-c]吡啶-6-氨基衍生物,直接或间接地通过与Mps激酶本身的相互作用来抑制单丝粒体1(Mps1 - 也称为TTK)激酶的纺锤体检查点功能。具体而言,本发明涉及将PPA衍生物用作治疗和/或预防增生性疾病,如癌症的治疗剂。本发明还涉及制备PPA衍生物的方法,以及包含它们的药物组合物。公式(I)
  • PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS
    申请人:Bavetsias Vassilios
    公开号:US20130345181A1
    公开(公告)日:2013-12-26
    The present invention relates to the use of certain pyrrolopyridineamino derivatives (hereinafter referred to as “PPA derivatives”), particularly 1H-pyrrolo[3,2-c]pyridine-6-amino derivatives, to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps kinase itself. In particular, the present invention relates to PPA derivatives for use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of the PPA derivatives, and pharmaceutical compositions comprising them. Formula (I)
    本发明涉及使用特定的吡咯吡啶氨基衍生物(以下简称为“PPA衍生物”),特别是1H-吡咯[3,2-c]吡啶-6-氨基衍生物,直接或间接地通过与Mps激酶本身的相互作用来抑制单丝粒体1(Mps1,也称为TTK)激酶的纺锤体检查点功能。具体而言,本发明涉及将PPA衍生物用作治疗和/或预防增生性疾病,如癌症的治疗剂。本发明还涉及制备PPA衍生物的方法,以及包含它们的药物组合物。公式(I)
  • 一种含有螺二芴的衍生物及其有机电致发光器件
    申请人:长春海谱润斯科技股份有限公司
    公开号:CN111848493B
    公开(公告)日:2022-10-14
    本发明提供了一种含有螺二芴的衍生物及其有机电致发光器件,涉及有机光电材料技术领域。本发明所要解决的技术问题是目前有机电致发光器件中空穴传输类材料稳定性差以及有机电致发光器件寿命短的问题。本发明的含有螺二芴的衍生物以螺二芴类的基团为母体,通过单键或者桥与咔唑并茚类基团连接。本发明的有机电致发光器件包括阳极、有机物层和阴极,有机物层包括空穴传输层。本发明式I的含有螺二芴的衍生物具有较适合的HOMO能级以及更好的稳定性,将其用于有机电致发光器件的空穴传输层时,有机电致发光器件具有较高的发光效率、较低的驱动电压以及较长的使用寿命。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐